, 6:143 | Cite as

Paracetamol (acetaminophen) esters of some non-steroidal anti-inflammatory carboxylic acids as mutual prodrugs with improved therapeutic index

  • T. A. Fadl
  • F. A. Omar


Paracetamol (acetaminophen) esters [4a-f] of some acidic NSAIDs were synthesized and evaluated as mutual prodrug forms with the aim of improving the therapeutic index through prevention of the gastrointestinal toxicity. The structures of the synthesized esters were confirmed by IR and 1H-NMR spectroscopy and their purity was established by elemental analyses and TLC. In-vitro stability studies revealed that the synthesized ester prodrugs 4a-f are sufficiently chemically stable in non-enzymatic simulated gastric fluid (hydrochloric acid buffer of pH 1.3 (t 1/2 ∼ 15–45 h)) and in phosphate buffer of pH 7.4 (t 1/2 ∼ 4–40 h). In 80% human plasma and 10% rat liver homogenate, the mutual prodrugs were found to be susceptible to enzymatic hydrolysis releasing the corresponding NSAID and paracetamol at relatively faster rates (t 1/2 ≈ 15–385 min and 1–140 min, respectively). Calculated log P values indicated that the prodrugs 4a-f are more lipophilic than the parent drugs.

In-vivo experiments in rabbits showed higher plasma levels of ibuprofen after oral administration of its ester prodrug 4b compared with those resulting from an equivalent amount of the corresponding physical mixture. Moreover, significant improvement in latency of pain threshold in mice has been observed up to 4 h after po administration of 0.02 mmol/kg of the prodrugs, compared with the corresponding physical mixtures. Gross observations and scanning electromicrographs of the stomach showed that the prodrugs induced very little irritancy in the gastric mucosa of mice after oral administration for 4 days. These results suggest that the synthesized mutual ester prodrugs were characterized by a better therapeutic index than the parent drugs.


paracetamol (acetaminophen) NSAIDs chemical and enzymatic stability ulcerogenicity pain threshold latency prodrugs 


  1. 1.
    Beck WS, Schneider HT, Dietzel K, Nuernberg B, Brune K. Gastrointestinal ulceration induced by antiinflammatory drugs in rats. Arch Toxicol. 1990;64:210–17.PubMedCrossRefGoogle Scholar
  2. 2.
    Rainsford KD. Gastrointestinal damage from NSAIDs. Toxicol Pathol. 1988;16:251–259.PubMedCrossRefGoogle Scholar
  3. 3.
    Jones G. Decreased toxicity and adverse reactions via prodrugs. In: Bundgaard H, ed. Design of Prodrugs. Amsterdam: Elsevier; 1985:199–241.Google Scholar
  4. 4.
    Cioli V, Putzolu S, Barcellona PS, Corradino C. The role of direct tissue contact in the production of GI ulcers by NSAIDs in rats. Toxicol Appl Pharmacol. 1979;50:283–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Shanbhag VR, Crider AM, Gokhale R, Harplani A, Dick RM. Ester and amide prodrugs of ibuprofen and naproxen: Synthesis and antiinflammatory activity, and gastrointestinal toxicity. J Pharm Sci. 1992;81:149–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Boyer TD, Rouff SC. Acetaminophen induced hepatic necrosis and renal failure. J Am Med Assoc. 1971;218:440–1.CrossRefGoogle Scholar
  7. 7.
    Vermeulen NPE, Straat RV, TeKoppele JM et al. Molecular mechanisms in toxicology and drug design. In: Classen V, ed. Trends in Drug Research, Vol. 13. Amsterdam: Elsevier; 1990:253–71.Google Scholar
  8. 8.
    Whitehouse MW, Rainsford KD. Esterification of acidic anti-inflammatory drugs supresses their gastrotoxicity without adversely affecting their anti-inflammatory activity in rats. J Pharm Pharmacol. 1980;32:795–6.PubMedGoogle Scholar
  9. 9.
    Bundgaard H, Nielsen NM. Glycolamide esters as a novel biolabile prodrug type for NSAI carboxylic acid drugs. Int J Pharmaceut. 1988;43:101–10.CrossRefGoogle Scholar
  10. 10.
    Omar FA. Cyclic amide derivatives as potential prodrugs. Synthesis and evaluation of N-hydroxymethylphthalimide esters of some NSAI carboxylic acid drugs. Eur J Med Chem. 1998;33 [in press].Google Scholar
  11. 11.
    Ogiso T, Iwaki M, Tanino T et al. Pharmacokinetics of indomethacin ester prodrugs: Gastrointestinal and hepatic toxicity and the hydrolytic capacity of various tissues in rats. Biol Pharm Bull. 1996;19:1178–83.PubMedGoogle Scholar
  12. 12.
    Kovach IM, Pitman IH, Higuchi T. Amino acid esters of phenols as prodrug: synthesis and stability of glycine, β-aspartic, and α-aspartic acid esters of p-acetamidophenol. J Pharm Sci. 1981;70:881–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Bousquet E, Marrazo A, Puglisi G, Spadaro A, Terindi S. Synthesis, physical properties, toxicological studies and bioavailability of l-pyroglutamic and l-glutamic acid esters of paracetamol as potentially useful prodrugs. J Pharm Pharmacol. 1996;48:479–85.PubMedGoogle Scholar
  14. 14.
    Shen TY. Non steroidal antiinflammatory agents. In: Wolf EM, ed. Burger’s Medicinal Chemistry, 4th edn, Part III. New York: John-Willey and Sons; 1980:1228.Google Scholar
  15. 15.
    Christiaans JAM, Timmerman H. Cardiovascular hybrid drugs: combination of more than one pharmacological property in one single molecule. Eur J Pharm Sci. 1996;4:1–22.CrossRefGoogle Scholar
  16. 16.
    Alex RR, Kulkarni VM. Design and synthesis of penicilloyl oxymethyl quinolone carbamates as a new class of dual-acting antibacterials. Eur J Med Chem. 1995;30:815–18.CrossRefGoogle Scholar
  17. 17.
    Scriba GKE. 3-Hydroxymethylphenytoin valproic acid ester, a new prodrug combining two anticonvulsant drugs. Arch Pharm Pharm Med Chem. 1996;329:554–5.CrossRefGoogle Scholar
  18. 18.
    Zahran MA, Kovacs L, El Sakka I, Pedersen EB, Nielsen C. The potential of aspirin in prodrug synthesis: A new potential delivery system of AZT and FLT. Arch Pharm Pharm Med Chem. 1996;329:417–20.CrossRefGoogle Scholar
  19. 19.
    Vigroux A, Bergon M, Zedde C. Cyclization-activated prodrugs: N-(substituted 2-hydroxylphenyl and 2-hydroxypropyl)carbamates based on ring-opened derivatives of active benzoxazolones and oxazolidinones as mutual prodrugs of acetaminophen. J Med Chem. 1995;38:3983–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Moffat AC, ed. Clark’s Isolation and Identification of Drugs. London: Pharmaceutical Press; 1986.Google Scholar
  21. 21.
    Leo AJ. Calculating log Poct from structures. Chem Rev. 1993;93:1281–1306.CrossRefGoogle Scholar
  22. 22.
    Khans AH, Bundgaard H. Prodrugs as delivery systems 107. Synthesis and chemical and enzymatic hydrolysis kinetics of various mono and diester prodrugs of N-acetylcysteine. Int J Pharmaceut. 1990;62:193–205.CrossRefGoogle Scholar
  23. 23.
    Omar FA, Mahfouz NM, Rahman M. Design, synthesis and antiinflammatory activity of some 1,3,4-oxadiazole derivatives. Eur J Med Chem. 1996;31:819–25.CrossRefGoogle Scholar
  24. 24.
    Galina ZH, Sutherland CJ, Amit Z. Effects of heat-stress on behaviour and the pituitary adrenal axis in rats. Pharmacol Biochem Behav. 1983;19:251–6.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • T. A. Fadl
    • 1
  • F. A. Omar
    • 1
  1. 1.Department of Pharmaceutical Medicinal Chemistry, Faculty of PharmacyAssiut UniversityAssiutEgypt

Personalised recommendations